Liu et al. demonstrated that miR-223 could remarkably inhibit differentiation of bone marrow cells (BMCs) into CD11b+Gr1+MDSCs in the presence of tumor-associated factors by targeting myocyte enhancer factor 2C (MEF2C) in vitro [67]. The gene discussed is ITGAM; the disease is neoplasm.